Why the study?
Does micronized fenofibrate compared to simvastatin improve atherogenic risk factors in patients with primary type IIa or IIb hyperlipidemia?
Population
60 patients with primary type IIa (n=32) or type IIb (n=28) hyperlipidemia
Comparison
Micronized fenofibrate 200 mg once daily for 3… vs Simvastatin 20 mg once daily for 3 months
Design
RCT, randomized, double-blind
Follow-up
3 months per treatment period
Authors
Loading...
Fenofibrate may be preferred for broader atherogenic factor control in mixed hyperlipidemia; extends RCT evidence for fibrates beyond LDL-C effects.
Does micronized fenofibrate compared to simvastatin improve atherogenic risk factors in patients with primary type IIa or IIb hyperlipidemia?
Fenofibrate and simvastatin similarly reduce total cholesterol and LDL-C, but fenofibrate has a broader spectrum of activity by also reducing triglycerides, Lp(a), and fibrinogen.
M. Farnier (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: